The notices it replaced
- Reissues: PA-21-259 PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 2 steps back: PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 3 steps back: PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed
- 4 steps back: PA-18-574 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 5 steps back: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 11 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 12 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 13 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 14 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-23-230.
Who won it before
7,012 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,943,074,724 in first-year total cost, median $293,438.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]284
- Special Emphasis Panel[ZRG1 ETTN-G (12)]236
- Special Emphasis Panel[ZRG1 IMST-H (15)]202
- Special Emphasis Panel[ZRG1 IDM-V (12)]185
- Special Emphasis Panel[ZRG1 IMST-B (12)]179
Most frequent institutions
- EPICYPHER, INC.46
- PHYSICAL SCIENCES, INC45
- AFFINERGY, LLC31
- MINNESOTA HEALTHSOLUTIONS CORPORATION28
- LYNNTECH, INC.27
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics2R44DA051309-02A1 | PAPPAS, GEORGE | SCHEDULE 1 THERAPEUTICS, INC., IL | $2,019,222 | ZRG1 |
| 2024 | Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH)1R44HL169052-01A1 | PALADINI, RUDY | HALO BIOSCIENCES, INC., CA | $1,957,305 | ZRG1 |
| 2024 | Measuring Whole and Tissue Level Bone Strength in men2R44AG071034-03A1 | BURKS, PETERTANG, SIMON YUE-CHEONG | ACTIVE LIFE SCIENTIFIC, INC., CA | $1,716,342 | ZRG1 |
| 2024 | Preclinical assessment of a novel compound for treating radiation-induced oral mucositis2R44DE031464-02 | LLOYD, COLTON JOSEPH | SINOPIA BIOSCIENCES, INC., CA | $1,493,635 | ZRG1 |
| 2024 | Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment2R44NS127712-02 | SUN, MIAO | VERSAPEUTICS INC, CA | $1,430,030 | ZRG1 |
| 2024 | Biochemical and genomic tools to study histone ADP ribosylation signaling1R44GM153000-01 | HUNT, SABRINA ROBINSUN, ZU-WEN | EPICYPHER, INC., NC | $1,274,494 | ZRG1 |
| 2024 | A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing2R44GM134776-04 | HOWELL, DAVID W. | BONDWELL TECHNOLOGIES LP, TX | $1,253,658 | ZRG1 |
| 2024 | A mobile application to offer upfront healthcare prices and automated medical billing for socioeconomically disadvantaged Americans2R44NR021119-03A1 | MARMOUSH, AHMED | HANDL HEALTH LLC, CA | $1,185,981 | ZRG1 |
| 2024 | Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis2R44HL165997-02 | YANG, JING | APLEXIS, INC., IL | $1,101,337 | ZRG1 |
| 2024 | Open Source Hearing Assessment System for Open Science1R44DC021123-01A1 | CLAVIER, ODILE H | CREARE, LLC, NH | $1,100,864 | ZRG1 |
| 2024 | A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells1R44DK136458-01A1 | THACHER, SCOTT MCNEAR | ORPHAGEN PHARMACEUTICALS, CA | $1,078,081 | ZRG1 |
| 2024 | SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections1R44AI177199-01A1 | HUTCHINS, JEFF T | INHALON BIOPHARMA, INC., NC | $1,024,986 | ZRG1 |
| 2024 | A novel flexible approach for high-throughput single-cell phenotyping and genotyping1R44HG013448-01 | SOUMILLON, MAGALI | FLEXOMICS LLC, MA | $1,009,871 | ZRG1 |
| 2024 | A Novel Anti-inflammatoryand Anti-oxidant Therapy for Treating Non-healing Diabetic Foot Ulcers1R44DK136463-01A1 | JACKSON, DAVID | CERIA THERAPEUTICS, INC., AZ | $1,006,408 | ZRG1 |
| 2024 | Direct-from-specimen identification of pathogens common in endocarditis2R44AI136064-05A1 | SINGER, ALON | HELIXBIND, INC., MA | $1,001,029 | ZRG1 |
| 2024 | A novel long-acting conjugate of the vasodilative hormone, human brain natriuretic peptide (hBNP), to treat resistant hypertension1R44HL169016-01A1 | JOHNSON, BRIAN LAURENCE | ANTLIA BIOSCIENCE INC, CA | $999,998 | ZRG1 |
| 2024 | High-content behavioral phenotyping of model organisms in three dimensions with a gigapixel microscope1R44OD036187-01 | HARFOUCHE, MARK | RAMONA OPTICS, INC., NC | $999,997 | ZRG1 |
| 2024 | Recombinant Outer Membrane Vesicles as a Novel Adjuvant for a Malaria Vaccine1R44AI181242-01 | LOCHER, CHRISTOPHER | VERSATOPE THERAPEUTICS, INC., MA | $999,762 | ZRG1 |
| 2024 | Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR)1R44AI181154-01 | BURKLUND, ALISONTADIMETY, AMOGHA | NANOPATHDX, INC., MA | $996,726 | ZRG1 |
| 2024 | A Vaccine for Lymphatic Filariasis, LFGuard™2R44AI140708-05 | CARTER, DARRICK ALBERTKALYANASUNDARAM, RAMASWAMY | PAI LIFE SCIENCES, INC., WA | $995,460 | ZRG1 |
| 2024 | Chikungunya Recombinant Subunit Vaccine2R44AI120388-05 | CLEMENTS, DAVID E | HAWAII BIOTECH, INC., HI | $967,053 | ZRG1 |
| 2024 | Advanced testing of a hexavalent adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment1R44AI181479-01 | KUTSCHER, HILLIARD | POP BIOTECHNOLOGIES, INC, NY | $950,225 | ZRG1 |
| 2024 | Establishment of a First-in-Class Biocompatible and Efficient Cryopreservation Technology Platform for the Next Generation of Cell-Based Therapeutics in Regenerative Medicine and Drug Discovery1R44OD035392-01A1 | HAN, XU | CRYOCRATE, LLC, MO | $940,821 | ZRG1 |
| 2024 | High throughput CAR-T potency assay based on functional and transcriptional measurements on single cell co-cultures1R44CA281575-01A1 | YELLEN, BENJAMIN BIRON | CELLDOM, INC., CA | $938,647 | ZRG1 |
| 2024 | A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection1R44DE033568-01 | FANGER, NEIL A | VIRTICI, LLC, WA | $923,623 | ZRG1 |
| 2024 | Autonomous Monitor for Toxic Gas Exposure2R44ES032369-02A1 | MICHALEK, JOHN ANTHONY | ZEBRA ANALYTIX, INC., AR | $919,218 | ZRG1 |
| 2024 | Multi-Media Professional Development for Parenting Educators to Deliver Oral Hygiene Education for Parents of Young Children2R44DE030019-02 | FEIL, EDWARD GUSTAVSMITH, DAVID RANDOLPH | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $908,824 | ZRG1 |
| 2024 | Hybridization Chain Reaction: Automated Ultrasensitive Multiplex RNA and Protein Imaging1R44GM153075-01 | CHOI, HARRY MING TAK | MOLECULAR INSTRUMENTS, INC., CA | $905,853 | ZRG1 |
| 2024 | Development of a web-based platform implementing novel Predictor of Toxicity for Medical Devices (PredTox/MD)2R44ES032371-02A1 | GOLBRAIKH, ALEXANDER | PREDICTIVE, LLC, NC | $898,248 | ZRG1 |
| 2024 | Development of a Route of Exposure Model Using Silicone Wristbands as Personal Samplers2R44ES033586-02A1 | O'CONNELL, STEVEN GEHRIG | MYEXPOSOME, INC., PA | $896,020 | ZRG1 |
| 2024 | Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma2R44HL160424-02A1 | BOITANO, SCOTTDEFEA, KATHRYN ANNE | PARMEDICS, INC., CA | $878,390 | ZRG1 |
| 2024 | REPTOR: accelerating antibody discovery and improving hits with machine learning2R44GM137688-02 | CASTELLANA, NATALIE | ABTERRA BIOSCIENCES, INC., CA | $856,396 | ZRG1 |
| 2024 | Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol1R44AI181252-01 | SHI, WANLIANG | PZA INNOVATION LLC, MD | $840,857 | ZRG1 |
| 2024 | Interactive Hand Hygiene Trainer for School-Age Children2R44GM144007-02A1 | CRILEY, JASMINKA | INDELIBLE LEARNING, INC., CA | $835,202 | ZRG1 |
| 2024 | Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases2R44EY030821-02 | TRAN, HIEP T | ABZYME THERAPEUTICS, LLC, PA | $831,927 | ZRG1 |
| 2024 | Synthetic PreImplantation Factor (sPIF) plus hypothermia to treat neonatal brain injury2R44HD100269-02 | BARNEA, EYTAN R | BIOINCEPT, LLC, OH | $831,440 | ZRG1 |
| 2024 | Advancing emergency medicine training with remote stereoscopic livestream technology2R44TR003956-02A1 | BAILEY, SHANNON KYLE TEDDERBURNS, MICHEAL | IMMERSIVE TECH, INC., FL | $758,394 | ZRG1 |
| 2024 | Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation1R44GM153003-01 | ZONG, GUANGHUI | GLYCOT THERAPEUTICS, LLC, MD | $758,302 | ZRG1 |
| 2024 | Fluorescence-based sequence-specific imaging of RNA modifications2R44GM137636-02A1 | TIAN, LING | MEDIOMICS, LLC, MO | $745,796 | ZRG1 |
| 2024 | Long term radiation treatment planning in brain tumors in the pediatric population1R44CA281709-01A1 | LEPORE, NATASHALOW, JUSTINOLCH, ARTHUR JACOB | VOXEL HEALTHCARE, LLC, CA | $718,740 | ZRG1 |
| 2024 | Multimodal intraoral camera1R44DE033307-01 | WILDER-SMITH, PETRA E | LIGHT RESEARCH, INC., AZ | $619,347 | ZRG1 |
| 2024 | Development of Smart Flocculants for the Treatment of PFAS Contaminated Water2R44ES032380-02A1 | HAUSER, ANASTASIAHILT, JAMES ZACH | BLUEGRASS ADVANCED MATERIALS, LLC, KY | $578,546 | ZRG1 |
| 2024 | In vitro myelination assay modeling the environment of MS lesions for predictive discovery of remyelinating therapies.1R43NS135867-01 | JAGIELSKA, ANNA | ARTIFICIAL AXON LABS INC., MA | $506,083 | ZRG1 |
| 2024 | Novel device for the repair and sealing of dural perforations in minimally invasive surgery1R43NS135645-01 | MAYBERG, MARC ROBERT | PATCHCLAMP MEDTECH, INC., WA | $499,956 | ZRG1 |
| 2024 | Wraparound digital health support system to improve engagement and health outcomes of minority populations who are disadvantaged by social determinants of health in evidence-based protocols2R44MD015981-02 | DUTTA, DEBOLEENA | VIORA HEALTH INC, PA | $499,721 | ZRG1 |
| 2024 | Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - Enclear Precision System1R44NS135792-01 | GLICKSMAN, MARCIE A | ENCLEAR THERAPIES, INC., MA | $494,693 | ZRG1 |
| 2024 | Extending the Ischemic Penumbra in Large Vessel Occlusion Stroke1R41NS129388-01A1 | NEMOTO, EDWIN M | SHEARIT, LLC, NM | $490,049 | ZRG1 |
| 2024 | Software-guided Operative Planning of MitraClip Placement1R44HL169034-01A1 | GUCCIONE, JULIUS MATTEOKASSAB, GHASSAN S | 3DT HOLDINGS, LLC, CA | $480,989 | ZRG1 |
| 2024 | Developing an "Out of the Box" Quality Improvement Library for Lung Diseases1R44HL172570-01 | TOBIAS, MARC | PHRASE HEALTH, INC., PA | $477,191 | ZRG1 |
| 2024 | A parallelized imaging platform for accurate and efficient long-term assessment of brain organoid development1R43MH133521-01A1 | HARFOUCHE, MARK | RAMONA OPTICS, INC., NC | $475,002 | ZRG1 |
| 2024 | A novel MICA/B based tumor-centric bispecific antibody that enhances NK cell activity in a hostile tumor microenvironment1R43CA287713-01 | BARUAH, HEMANTA | AAKHA BIOLOGICS INC., TX | $400,000 | ZRG1 |
| 2024 | Accurate prognosis and prediction of clinical benefits of adjuvant therapy for early-stage non-small cell lung cancer1R43CA281430-01A1 | GUO, NANCY LANYE, QING | SOSTOS LLC, WV | $400,000 | ZRG1 |
| 2024 | A novel targeted antibody therapeutic to treat ovarian cancer1R43CA287501-01 | LAUS, REINER | TRIO PHARMACEUTICALS INC., CA | $399,478 | ZRG1 |
| 2024 | A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies1R43HG013446-01 | SPUHLER, PHILIPP STEFAN | SANSIMEON, INC, CA | $399,369 | ZRG1 |
| 2024 | Targeting proton-sensing GPR68 as a ferroptosis-based therapy for glioblastoma1R43CA287513-01 | WILLIAMS, CHARLES HOUSTON | PROTON BIO, INC., MD | $399,214 | ZRG1 |
| 2024 | Engager T cell: A Simple Solution for Off-the-shelf T Cell Therapy for Cancer1R43CA281523-01A1 | LI, GONGBO | IMMUNEBRO THERAPEUTICS INC., IL | $361,635 | ZRG1 |
| 2024 | A rapid method for global and targeted miRNA next generation sequencing1R43HG013444-01 | RAO, VARSHA | CLARET BIOSCIENCE, LLC, MI | $358,579 | ZRG1 |
| 2024 | Development of Novel Immunoregulatory Therapeutics for Asthma1R43HL172516-01 | BASSAGANYA-RIERA, JOSEP | BIOTHERAPEUTICS, INC., VA | $355,935 | ZRG1 |
| 2024 | Testing Novel Advancements to Recombinant Heparin Production1R43HL172567-01 | GLASS, CHARLES ALEXANDER | TEGA THERAPEUTICS, INC., CA | $355,222 | ZRG1 |
| 2024 | Topical treatment for burn pain by blocking cutaneous pain receptors.1R43GM150295-01A1 | BHARGAVA, KUMARIL | SERENTRIX, LLC, PA | $340,685 | ZRG1 |
| 2024 | LentiSAFE Ligands: Mild-Elution Immunoaffinity Ligands for Enrichment and Purification of Lentiviral Vectors1R43TR004551-01A1 | ONAKUNLE, YEMI | MABSWITCH, INC., CA | $338,997 | ZRG1 |
| 2024 | Using an Inclined Plane System to Triage TBI Patients1R43NS135862-01 | GALEN, PETER | HEMEX HEALTH, INC., OR | $332,122 | ZRG1 |
| 2024 | Enhanced Gene Therapy Delivery Through Electric Pulsing Double-Balloon Catheter1R43TR004536-01A1 | HAGNESS, SUSAN CPHILLIPS, JANET | VECTOR SURGICAL, LLC, WI | $331,034 | ZRG1 |
| 2024 | Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells1R43GM153144-01 | RAMUNAS, JOHN | REJUVENATION TECHNOLOGIES, INC., CA | $324,998 | ZRG1 |
| 2024 | Programmable Microfluidic Perfusion Bioreactor for 3D Organoid Culture and Screening Applications1R43HL172397-01 | MYERS, FRANK | MOSAIC ENGINEERING LLC, CA | $321,963 | ZRG1 |
| 2024 | Development of IFNA2-LNP01 for tumor lung metastases immunotherapy1R43CA287611-01 | REDD, PRISCILLA SIMON | CHEMEDIMMUNE, INC., GA | $320,597 | ZRG1 |
| 2024 | Novel Gene Therapy, Techniques, and Devices to Prevent Ventricular Tachycardia1R44HL172541-01 | ANDERSON, RONALD LEE | RITHIM BIOLOGICS, INC., MD | $317,285 | ZRG1 |
| 2024 | Development of Quantitative In Vivo Imaging of Oral Biofilm pH to Allow Prevention of Enamel Demineralization1R43DE032985-01A1 | MCMORROW, GERALD | VERAVANTI, INC., WA | $309,428 | ZRG1 |
| 2024 | A new class of antiviral directed at HBV capsid protein1R43AI181057-01 | NAIR, SMITA | DOOR PHARMACEUTICALS, LLC, IN | $306,500 | ZRG1 |
| 2024 | Device Automation of an FDA-cleared CD-Microfluidic Platform for Rapid Tissue Microsizing1R43TR004975-01 | ZOBI, AHMED NABIL | SYNTR HEALTH TECHNOLOGIES, LLC, CA | $306,161 | ZRG1 |
| 2024 | Novel therapy to prevent alveolar bone loss in severe periodontitis1R43DE033577-01 | BOR, BATBILEGLARRICK, JAMES WMENDELSOHN, ANDREW R | PANORAMA RESEARCH, INC., CA | $304,019 | ZRG1 |
| 2024 | Head-mounted, high-speed confocal imager for voltage-sensitive neuronal recording1R43MH126790-01A1 | YOO, HYEJIN | PHYSICAL SCIENCES, INC, MA | $300,837 | ZRG1 |
| 2024 | Pharmacological rejuvenation of human hematopoietic stem cells1R43HL172285-01 | MULLOY, JAMES CZHENG, YI | MOGLING BIO INC, OH | $299,781 | ZRG1 |
| 2024 | Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist1R43AI181292-01 | KAILASAN, SHWETA | ABVACC, INC., MD | $299,528 | ZRG1 |
| 2024 | Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens1R44AI181163-01 | PARENT, STEPHEN | KATHERA BIOSCIENCE INC., NJ | $298,530 | ZRG1 |
| 2024 | Rapid, versatile PCR1R43AI181390-01 | FARIS, GREGORY W | NUMENTUS TECHNOLOGIES INC., CA | $297,872 | ZRG1 |
| 2024 | E. coli platform for expression of low-cost malaria fusion proteins1R43AI181078-01 | LEES, ANDREW | FINA BIOSOLUTIONS, LLC, MD | $297,809 | ZRG1 |
| 2024 | Slippery, Omniphobic Coating to Prevent Thrombosis and Biofilm Formation on Peripheral Vascular Grafts1R44HL172473-01 | MCFARLAND, TODDMYERS, DANIEL DURANTOBI, ANDREA TARA | CERULEAN SCIENTIFIC INC., PA | $297,732 | ZRG1 |
| 2024 | Development of circRNA manufacturing platform in yeast1R43TR004890-01 | PICKERING, BRIAN FREDERICK | CHIMERNA THERAPEUTICS INC., NY | $297,608 | ZRG1 |
| 2024 | Advanced 3D model of the Human Cornea for Keratoconus1R43EY035893-01 | ROEHM, KEVIN | CFD RESEARCH CORPORATION, AL | $297,153 | ZRG1 |
| 2024 | Development of Heterobivalent Small-Molecule Therapeutics for the Treatment of Triple-Negative Breast Cancer1R43CA287494-01 | COGNETTA, ARMAND | WEATHERWAX BIOTECHNOLOGIES CORPORATION, CA | $296,286 | ZRG1 |
| 2024 | Improving survival from Burkholderia pseudomallei and other pathogenic intracellular bacteria1R43AI181293-01 | COX, GEORGE NORBERT | BOLDER BIOTECHNOLOGY, INC., CO | $295,924 | ZRG1 |
| 2024 | Multiplexed Nuclear Receptor BioAssay platform to inexpensively and broadly survey the nation's water supply for contamination by endocrine disrupting chemicals1R43ES036049-01 | SCHAUFELE, FRED J | XCELLASSAY, INC., CA | $295,923 | ZRG1 |
| 2024 | HealthyU-Native: A Technology-Based Tool for Addressing Health Literacy in Native American/Alaska Native Secondary Students1R43MD019203-01 | HAMILTON, ALEXANDRAHUSCROFT-D'ANGELO, JACQUELINEMARQUEZ, JESSIE | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $295,922 | ZRG1 |
| 2024 | Quantitative measurement of PlGF using a rapid, low-cost, point-of-care (POC) diagnostic platform for prediction and detection of pre-eclampsia1R43HL172410-01 | SEIMETZ, JOSEPH | RICOVR HEALTHCARE INC., NJ | $295,895 | ZRG1 |
| 2024 | Smart CSF Delivery System for CNS Drug Therapy for Leptomeningeal Disease1R43CA281429-01A1 | GLICKSMAN, MARCIE A | ENCLEAR THERAPIES, INC., MA | $295,851 | ZRG1 |
| 2024 | Development of a high throughput in vivo screening platform for identifying novel pro-and postbiotic bacterial strains1R43AT012449-01A1 | QURESHI, MOHAMMED ADNAN MOHAMMED HANIF | NEMALIFE INC., TX | $295,780 | ZRG1 |
| 2024 | Device for assessment of 8th nerve function and cochlear implant candidacy1R43DC021116-01A1 | DELGADO, RAFAEL E | INTELLIGENT HEARING SYSTEMS, FL | $295,770 | ZRG1 |
| 2024 | BioBricks-Env: AI driven, open-source, modular, composable platform to organize, store, retrieve, extract, and integrate environmental health & risk related data1R43ES036069-01 | LUECHTEFELD, THOMAS | INSILICA, LLC, MD | $295,662 | ZRG1 |
| 2024 | Advancement of a Point-of-Need (PoN) platform device for accurate and destigmatized detection of recent cannabis use1R43DA059318-01 | SEIMETZ, JOSEPH | RICOVR HEALTHCARE INC., NJ | $295,606 | ZRG1 |
| 2024 | Development of a safe and effective topically administered pharmacotherapy to treat acute corneal pain1R43EY035872-01 | FONG, TUNGSOPPIMATH, KUMARESH | VYLUMA INC., NJ | $295,086 | ZRG1 |
| 2024 | Delivering genetic medicines to photoreceptors with lipid nanoparticles1R43EY035865-01 | TUTTLE, ADAM | ENTERX BIOSCIENCES, INC., OR | $294,052 | ZRG1 |
| 2024 | Hybrid surgical stapler with tissue sensing technology1R43EB035458-01 | WENCHELL, THOMAS GEORGE | REVMEDICA, INC., CT | $293,989 | ZRG1 |
| 2024 | Development of H.E.R.O. (Health/care environment for research or organizations): A platform to develop, host, and maintain digital health interventions and programs1R43LM014476-01 | MITCHELL, JASON WUDUPI, SANTHOSH K | NESTOTUS LLC, MI | $293,978 | ZRG1 |
| 2024 | srvc-EHSR: Sysrev Version Control - Environmental and Health Related Systematic Reviews1R43ES035359-01A1 | LUECHTEFELD, THOMAS | INSILICA, LLC, MD | $293,741 | ZRG1 |
| 2024 | A Spatially Uniform Illumination Source for Widefield Multi-Spectral Optical Imaging1R43NS135877-01 | SEYMOUR, ELIF | IRIS KINETICS INC, MA | $293,588 | ZRG1 |
| 2024 | A novel mobile phone technology to improve access for preeclampsia and hypertension detection1R43HL172484-01 | HEIRONIMUS, JOHN CONRADHUECKER , MARTIN RICHARDWOLFSON, DAVID | TELE-STETHOSCOPE INC., KY | $292,897 | ZRG1 |
| 2024 | IND-enabling development of MM010, a PEG-specific intervention that blocks allergic response and restores repeated dosing for select PEGylated medicines impacted by anti-PEG antibody1R43AI181354-01 | KUSHIRO, KEIICHIRO | MUCOMMUNE, LLC, NC | $291,458 | ZRG1 |
| 2024 | Novel Biosensor for Detection of Endotoxin1R43TR004888-01 | QUIJANO RUBIO, ALFREDO | MONOD BIO, INC., WA | $290,066 | ZRG1 |
| 2024 | Artificial Intelligence Tool to Optimize Organ Transplantation Outcomes (Transplant-AI)1R44HL172564-01 | HAVELKA, JIM | INFORMAI, INC., TX | $289,762 | ZRG1 |
| 2024 | A Palette of Near-Infrared Voltage Sensors for Cardiac Research and Safety Pharmacology1R43HL172546-01 | ACKER, COREY | POTENTIOMETRIC PROBES, LLC, CT | $282,266 | ZRG1 |
| 2024 | A Numerical Platform for Microbubble Enhanced Sonothrombolysis1R43HL172528-01 | MA, JINGSEN | DYNAFLOW, INC., MD | $281,956 | ZRG1 |
| 2024 | Cholesterol Removal as a Treatment for Dry Age-Related Macular Degeneration1R43EY035876-01 | MEHTA, NEHAL N | MOBIUS SCIENTIFIC INC., DC | $276,758 | ZRG1 |
| 2024 | A new platform for inexpensive and scalable recombinant protein and growth factor production to support cell culture applications in therapeutics.1R43GM146560-01A1 | LIANG, JULIE MING | OPERA BIOSCIENCE, INC., IL | $275,765 | ZRG1 |
| 2024 | Non-metallic earbuds for auditory stimuli in MRI scanners1R43DC021136-01A1 | VON WIEGAND, THOMAS EDWARD | SENSIMETRICS CORPORATION, MA | $275,765 | ZRG1 |
| 2024 | Accurate and cost-effective detection of mutagenicity and mutagenic exposure1R43ES036101-01 | MASLOV, ALEXANDER Y.SHARIFI, MOHAMED SAMIN | MUTAGENTECH, INC., NY | $275,763 | ZRG1 |
| 2024 | 3STEP: A swab-seal-read, point-of-care nucleic acid test to address disparity in STI screening and prevention1R43AI181122-01 | MULLINS, BRIANNAWARRICK, JAY WYATT | SALUS DISCOVERY, LLC, WI | $275,736 | ZRG1 |
| 2024 | Development of an Extracochlear Device to Restore Hearing1R43DC021615-01 | WONG, FRANCIS | AURICLE HEALTH INC, CA | $275,371 | ZRG1 |
| 2024 | Developing a novel epigenetic regulator as a treatment for opioid use disorder1R43DA058603-01A1 | KIM, THOMAS | EPIVARIO, LLC, PA | $275,253 | ZRG1 |
| 2024 | High Efficiency Sorption System for Removing Harmful Contaminants from Indoor Air1R43ES036089-01 | JAYARAMAN, AMBALAVANAN | TDA RESEARCH, INC., CO | $274,853 | ZRG1 |
| 2024 | Development of next-generation biologics programmed with multifunctional synthetic chemistries1R43GM150368-01A1 | CHATTOPADHYAY, SOUVIK | PEARL BIO, INC., MA | $274,692 | ZRG1 |
| 2024 | EcoWell- A planet in a plate.1R44ES036060-01 | ELL, BRIANSNOWFLACK, DANIELLESYKORA, PETER | AMELIA TECHNOLOGIES, LLC, DC | $274,458 | ZRG1 |
| 2024 | Democratizing statistical computing through AI1R43GM153076-01 | BURKHALTER, DANIEL | RTUTOR, LLC, SD | $273,987 | ZRG1 |
| 2024 | A novel and inexpensive multiplex miRNA platform for liver diseases screening1R43AA031448-01 | BALA, SHASHI | KASA BIO, L.L.C., GA | $273,974 | ZRG1 |
| 2024 | Binding free energy predictions for peptide drugs: A novel machine learning-based peptide simulation model for high-throughput computational lead optimization with quantum mechanical accuracy.1R43GM152994-01 | WHITE, ALEC | QUANTUM SIMULATION TECHNOLOGIES, INC., MA | $272,369 | ZRG1 |
| 2024 | High Mass MALDI TOF Employing a Novel High-Tc Superconducting Ion Detector1R43GM153742-01 | BERKOUT, VADYM D | ZETEO TECH, INC., MD | $271,495 | ZRG1 |
| 2024 | A smart wearable contact microphone patch for extended and remote monitoring of lung functions1R43HL167472-01A1 | WEN, HAORAN | STETH X MICROSYSTEMS, INC., GA | $269,922 | ZRG1 |
| 2024 | Ubiquitin pathway modulators for treating pancreatitis1R43DK138712-01 | SURESH, KUMAR | PROGENRA, INC., PA | $269,622 | ZRG1 |
| 2024 | System on Chip for Intraoperative OCT1R43EY035946-01 | AL-QAISI, MUHAMMAD | MYRIAD ADVANCED TECHNOLOGIES LLC, CA | $269,472 | ZRG1 |
| 2024 | Single cell tri-omics: High coverage simultaneous profiling of DNA, RNA, and proteins in single cells1R43NS135703-01 | PRINCE, ROBIN | FLUID DISCOVERY INC, CA | $268,142 | ZRG1 |
| 2024 | Point-of-care viral load monitoring to support large-scale clinical testing of new HIV cure strategies1R43AI181436-01 | PRINCE, ROBIN | FLUID DISCOVERY INC, CA | $268,142 | ZRG1 |
| 2024 | Improving the effectiveness of anti-tuberculosis drugs by developing a point-of-care therapeutic drug monitoring system for areas with limited medical resources1R43AI181155-01 | LAN, TIAN | GLUCOSENTIENT, INC., IL | $265,773 | ZRG1 |
| 2024 | Development of POC system for patient condition and treatment monitoring in Sickle Cell Disease through hypoxia-induced sickling1R43HL172384-01 | HINES, PATRICK | FUNCTIONAL FLUIDICS, LLC, MI | $265,347 | ZRG1 |
| 2024 | Developing a Novel Incubator to Increase Cell Culture Reproducibility1R44TR004569-01A1 | ROTHENBERG, BARRY E. | EMBRIENT INC, CA | $262,240 | ZRG1 |
| 2024 | Evolving the standard of care for carbapenem resistant infections, through the development of a phenotypic assay capable of DETECTing and classifying carbapenemases1R43AI181482-01 | JACKSON, NICOLE | BIOAMP DIAGNOSTICS, INC., CA | $243,806 | ZRG1 |
| 2024 | GlyCoSAM: Glycolysis coupled S-adenosyl methionine regeneration for cell-free methylation reactions1R43GM153108-01 | BRUECKNER, ADRIAN | INVIZYNE TECHNOLOGIES, INC., CA | $243,527 | ZRG1 |
| 2024 | DNA-optical barcoding technology for spatiotemporal single-cell analysis1R44HG013591-01 | KWOK, SHELDON J.J. | LASE INNOVATION INC., MA | $239,680 | ZRG1 |
| 2024 | An In Chemico Test to Identify Dermal Corrosives1R44ES036065-01 | LEBRUN, STEWART | LEBRUN LABS, LLC, CA | $238,257 | ZRG1 |
| 2024 | DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)1R43CA287836-01 | SUBRAMANIAM, VISH V. | EMBIOSYS INC., MA | $211,125 | ZRG1 |
| 2024 | Synthetic Egg:Sperm Fusion Assay (SEFA): A Diagnostic Test for Male Fertility1R43HD114303-01 | LYSIAK, JEFFREY J | PS-FERTILITY, INC., VA | $195,000 | ZRG1 |
| 2024 | Advanced Water Treatment System for On-Site PFAS Capture and Destruction1R43ES036038-01 | WANG, MENG | ENSPIRED SOLUTIONS INC., MI | $179,465 | ZRG1 |
| 2024 | Development of Microwave Induced Membrane Distillation with Carbon Nanotube Immobilized Membranes: A Sustainable Solution for Solvent Recovery from Aqueous Wastes1R43ES036050-01 | LI, CHENG | NANOSEPEX INC., NJ | $168,337 | ZRG1 |
| 2024 | Stress, Mindfulness, and People with Intellectual Disabilities1R43MH135535-01A1 | SHEEHAN, MARTIN R. | DOUBLE S INSTRUCTIONAL SYSTEMS, OR | $135,214 | ZRG1 |
| 2023 | A youth-specific helmet for preventing traumatic brain injury2R44NS119134-03A1 · under PA-21-259 | AVERY, GORDONCECCHI, NICHOLAS JAMES | SAVIOR BRAIN INC., VA | $2,864,855 | ZRG1 |
| 2023 | Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorderand Tolerance in the Treatment of Pain1R44DA059302-01 | MEYN, MALCOLM A | AMALGENT THERAPEUTICS, INC., NC | $2,579,875 | ZRG1 |
| 2023 | Toxicology and Efficacy Studies of Intrathecal VersaMab-101 for spinal cord injury treatment2R44NS120397-02 | SUN, MIAO | VERSAPEUTICS INC, CA | $2,380,552 | ZRG1 |
| 2023 | A Novel Opioid-Free Targeted Pain Control Method for Acute Post-Operative Localized Pain Related to Oral Surgical Procedures2R44DE029369-02 | JADIA, RAHULKAY, GEORGE | REVBIO, INC., MA | $2,050,357 | ZRG1 |
| 2023 | RSK3 Anchoring Disruptor Therapy for Heart Failure1R44HL167349-01A1 | CIVIDINI, FEDERICO | CARDIAC RSK3 INHIBITORS, LLC, CA | $1,978,293 | ZRG1 |
| 2023 | Automated lab identification and sorting (Rapid-IDX) for mosquito surveillance2R44GH002369-02 | BREY, JEWELL AMANDA | VECTECH, LLC, MD | $1,962,860 | ZRG1 |
| 2023 | Targeting galectin-3 to overcome insulin resistance in type 2 diabetes2R44DK125126-02 | AHMED, HAFIZ | GLYCOMANTRA, INC., MD | $1,810,483 | ZRG1 |
| 2023 | BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning1R44MH135521-01 | LEWARCH, CAITLIN LEIGHWILLIAMS, LUIS ALBERTO | QUIVER BIOSCIENCE INC., MA | $1,721,943 | ZRG1 |
| 2023 | Multi-functional anti-thrombotic therapy for coronary microvascular obstruction1R44HL169132-01 | CHEN, RIDONG | APT THERAPEUTICS, INC., IL | $1,582,022 | ZRG1 |
| 2023 | Using Machine Learning and Blockchain Technology to Reduce Drug Diversion in Hospitals2R44DA051084-02A1 | GHOLAMI, BEHNOOD | AUTONOMOUS HEALTHCARE, INC., CA | $1,577,231 | ZRG1 |
| 2023 | Innovative 3D Printed Intravaginal Ring AnelleO-PRO, the first Single Administration of Progesterone for Infertility2R44HD100190-04 | BENHABBOUR, SOUMYA RAHIMAJANUSZIEWICZ, RIMA | ANELLEO, INC., NC | $1,570,185 | ZRG1 |
| 2023 | Low-Dose Magneto-Thrombolysis to Expand Stroke Care1R44NS132605-01 | CREIGHTON, FRANCIS MILTONDERDEYN, COLIN PIETER | UNANDUP, LLC, MO | $1,523,833 | ZRG1 |
| 2023 | Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)1R44NS134453-01 | CRAMER, CAROLE L.PATTADA, SHIVAKUMAR DEVAIAH | BIOSTRATEGIES, LC, AR | $1,500,000 | ZRG1 |
| 2023 | Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD1R44AG085411-01 · under PA-21-259 | ALWORTH, SAMUEL VFENG, ZHIHUA | ACURASTEM, INC., CA | $1,492,509 | ZRG1 |
| 2023 | Commercial translation of high-density carbon fiber electrode arrays for multi-modal analysis of neural microcircuits1R44NS134432-01 | BHANDARI, RAJMOHANCHESTEK, CYNTHIA ANNEPOWELL, DANIELSOLZBACHER, FLORIAN | BLACKROCK MICROSYSTEMS, UT | $1,487,586 | ZRG1 |
| 2023 | Implementing a coupled system of integrative ML modeling and data validation for elucidating microglial therapeutic targets in neurodegenerative disease1R44MH135465-01 | SACHS, KAREN | MODULO BIO, INC., CA | $1,457,344 | ZRG1 |
| 2023 | Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD1R44NS132698-01 | FENG, ZHIHUASAZANI, PETER | ACURASTEM, INC., CA | $1,390,906 | ZRG1 |
| 2023 | A democratized platform for mapping the spatial epigenome in tissue1R44CA287890-01 | SABINA, JEFFREY | ATLASXOMICS INC., CT | $1,390,826 | ZRG1 |
| 2023 | A Disease-Modifying Protein Therapeutic for the Treatment of COPD2R44HL149580-02 · under PA-21-259 | PRINCE, CHRISTOPHER LUCAS | VERRA THERAPEUTICS, INC., NY | $1,364,498 | ZRG1 |
| 2023 | Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer2R44CA265503-02A1 | ROTOLO, JIM | SAPIENCE THERAPEUTICS, INC., NY | $1,362,268 | ZRG1 |
| 2023 | Multi-modal spatial genomics in the mouse and human brains1R44MH133530-01A1 | FRIEDA, KIRSTEN | SPATIAL GENOMICS, INC., CA | $1,337,968 | ZRG1 |
| 2023 | The Alara Imaging Gateway: Linking Electronic Health Records and Radiology Imaging Exams to Report on National Quality Measures to Reduce Cancer Risk from Computed Tomography (Alara Imaging Gateway)1R44CA287536-01 | MAZONSON, NATHAN | ALARA IMAGING INC., CT | $1,316,275 | ZRG1 |
| 2023 | Ethnically Diverse iPSC-Cardiomyocyte Panel for Pharmacogenomics and Drug Safety Testing1R44HL170756-01 | AHMED, SYED MUKHTAR | GREENSTONE BIOSCIENCES, INC., CA | $1,294,681 | ZRG1 |
| 2023 | Development of a novel peptide therapeutic for traumatic brain injury1R44NS130776-01 · under PA-21-259 | MANN, AMAN | AIVOCODE, LLP, CA | $1,290,957 | ZRG1 |
| 2023 | Novel recombinant sensors to study histone ubiquitin signaling1R44GM149036-01 · under PA-21-259 | SUN, ZU-WEN | EPICYPHER, INC., NC | $1,276,822 | ZRG1 |
| 2023 | Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map1R44GM149095-01A1 | REDDY, BOBBY | PRENOSIS, INC., IL | $1,272,176 | ZRG1 |
| 2023 | Development of a Novel Bone Adhesive Scaffold to Accelerate Bone Regeneration and Improve Ridge Height Maintenance for the Treatment of Patients with Residual Ridge Resorption1R44DE032564-01 · under PA-21-259 | JADIA, RAHULKAY, GEORGE | REVBIO, INC., MA | $1,265,448 | ZRG1 |
| 2023 | HEALS™: An Active Hydrogen Sulfide Delivery Technique for Accelerated, Effective Wound Healing2R44GM144027-02 | SHEKARRIZ, REZA | EXHALIX, LLC, NM | $1,244,870 | ZRG1 |
| 2023 | IND Enabling Studies for the Development of Pruritus Therapeutic PRA-5232R44AR081768-02 | PIPPIN, DOUGLAS ANTHONY | PRAEVENTIX, LLC, PA | $1,244,708 | ZRG1 |
| 2023 | TempO-LINC high throughput high sensitivity single cell gene expression profiling assay Ph II2R44GM140771-02 | SELIGMANN, BRUCE E. | BIOSPYDER TECHNOLOGIES, INC., CA | $1,241,285 | ZRG1 |
| 2023 | 3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection2R44AR083836-02 | BOCK, RYAN | SINTX TECHNOLOGIES, INC., UT | $1,227,401 | ZRG1 |
| 2023 | IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis2R44DK117687-04 | AUCI, DOMINICKEGILMEZ, NEJAT K | THERAPYX, INC., NY | $1,201,534 | ZRG1 |
| 2023 | Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation1R44CA281497-01A1 | JOHNSON, RICHARD | SAROS THERAPEUTICS INC, IL | $1,196,731 | ZRG1 |
| 2023 | Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters2R42HL149595-02A1 | SHEBUSKI, RONALD J. | NYTRICX INC., GA | $1,193,055 | ZRG1 |
| 2023 | Expansion and validation of novel mobile app for guiding home modifications for aging in place2R44AG067804-02 · under PA-21-259 | TENENBAUM, LOUIS | HOMESRENEWED VENTURES LLC, DC | $1,170,977 | ZRG1 |
| 2023 | ViTrack: Wearable, accurate, continuous blood pressure monitor to improve outcomes in hypertensive diseases of pregnancy1R44HL167356-01 · under PA-21-259 | THANIKACHALAM, MOHAN | DYNOCARDIA, INC., MA | $1,168,681 | ZRG1 |
| 2023 | Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis1R44GM149065-01 · under PA-21-259 | REDDY, BOBBY | PRENOSIS, INC., IL | $1,161,624 | ZRG1 |
| 2023 | Development of Cortical Bone Mechanics Technology for Enhancing the Diagnosis of Osteoporosis2R44AG058312-04 | CLARK, BRIAN CDICK, ANDREW | OSTEODX INC., OH | $1,160,485 | ZRG1 |
| 2023 | Development of CA-IL-12 for Triple Negative Breast Cancer2R44CA250887-02A1 | FILARDO, EDWARD J | CYTONUS THERAPEUTICS, INC., OH | $1,148,542 | ZRG1 |
| 2023 | Commercialization of methods and reagents for high-throughput single cell analysis2R44GM137648-02 | FONTANEZ, KRISTINA | FLUENT BIOSCIENCES INC., MA | $1,146,224 | ZRG1 |
| 2023 | The Point Powered: A Robust Actuated Prosthetic Finger for Partial Hand Amputation2R44EB030895-02 | SLIKER, LEVIN | POINT DESIGNS, LLC, CO | $1,142,929 | ZRG1 |
| 2023 | Treating non-small cell lung tumors with a novel inhaled dry powder chemotherapeutic formulation1R44CA277898-01A1 | BEVERLIN II, BRYCE | QUENCH MEDICAL, INC., MN | $1,127,538 | ZRG1 |
| 2023 | Method for the validation by Western analysis of affinity reagents against post-translationally modified proteins.2R44GM146473-02 | WEINER, MICHAEL P | ABBRATECH, INC., CT | $1,121,971 | ZRG1 |
| 2023 | A Novel, Low-Cost, Handheld, 3D Imaging System for Improved Screening of Cervical Neoplasia in Resource Limited Settings2R44CA254586-02 | CARSON, JOSEPH | PENSIEVISION, INC., CA | $1,116,921 | ZRG1 |
| 2023 | Rapid NGS Method for Mapping of the Epitranscriptome2R44HG012534-02 | STENGEL, GUDRUN | ALIDA BIOSCIENCES, INC., CA | $1,107,445 | ZRG1 |
| 2023 | Strain-Programmed Bioadhesive Patch for Enhanced Diabetic Wound Healing1R44DK137615-01A1 | YUK, HYUNWOO | SANAHEAL, INC., MA | $1,105,432 | ZRG1 |
| 2023 | Development of a high precision and high order DNA counting platform1R44GM149104-01 · under PA-21-259 | SHUM, ELEEN YEE LAM | ENUMERIX, INC., CA | $1,080,705 | ZRG1 |
| 2023 | Platform for the High Throughput Generation and Validation of Affinity Reagents1R44GM148998-01 · under PA-21-259 | WEINER, MICHAEL P | ABBRATECH, INC., CT | $1,080,240 | ZRG1 |
| 2023 | Development of An Innovative TEE Technology for Mutation Detection1R44CA284965-01 | DENG, QIPANGUO, BAOCHUAN | GLC BIOTECHNOLOGY, INC., OH | $1,071,571 | ZRG1 |
| 2023 | Novel Broad-Spectrum Point-of-Care Coagulometer1R44HL169158-01 | BAKHRU, SASHA H | PEROSPHERE TECHNOLOGIES INC., CT | $1,068,783 | ZRG1 |
| 2023 | ADDITIVE MANUFACTURING OF PDMS MICROFLUIDICS2R44TR003968-02 | SCHULTZ, JEFFREY | PHASE, INC., NC | $1,066,595 | ZRG1 |
| 2023 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma2R44CA250616-02 | RAMIREZ, CRAIG PATRICK | TEZCAT LABORATORIES LLC, CT | $1,062,082 | ZRG1 |
| 2023 | Development of an innovative neurosurgical planning tool for awake craniotomy1R44MH135726-01 | SIMS, MAXWELL HARRISON | MINDTRACE TECHNOLOGIES, INC., PA | $1,050,668 | ZRG1 |
| 2023 | Diagnostic tool for assessment and tracking of microbial load in bloodstream infections1R44AI174578-01 · under PA-21-259 | SINGER, ALON | HELIXBIND, INC., MA | $1,050,000 | ZRG1 |
| 2023 | Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle2R44AI152788-03 · under PA-21-259 | MCDONNELL, MARK E | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,050,000 | ZRG1 |
| 2023 | Rapid, Handheld, Point-of-Care Stool Sample-prep Device for the Extraction and Detection of Nucleic Acid from Diarrheal Pathogens2R44AI155367-02 · under PA-21-259 | KIM, CHANG HEE | GODX, INC., WI | $1,050,000 | ZRG1 |
| 2023 | XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies1R44AI179564-01 | KEARNEY, BRIAN | EXAVIR THERAPEUTICS INC., CA | $1,049,975 | ZRG1 |
| 2023 | In vivo delivery of Ab-directed CRISPR ribonucleoproteins for anal cancer immunotherapy1R44CA287699-01 | HAAK-FRENDSCHO, MARY | SPOTLIGHT THERAPEUTICS, CA | $1,043,843 | ZRG1 |
| 2023 | Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform1R44CA281474-01 | MEDINA, JUAN SANTIAGO | ISABL INC., NY | $1,041,487 | ZRG1 |
| 2023 | Mitigation of Radiation Induced Gastrointestinal Syndrome.1R44AI177220-01 | NORRIS, ANDREW JOHNSAHA, SUBHRAJIT | BCN BIOSCIENCES, LLC, CA | $1,034,934 | ZRG1 |
| 2023 | Development of a High Throughput Assay for Rapid Screening of Congenital Cytomegalovirus Infection using Dried Blood Spots2R44DC019890-02 | STOWE, RAYMOND PRESTON | MICROGEN, LLC, TX | $1,034,453 | ZRG1 |
| 2023 | Point of Care maternal milk concentration device to optimize neonatal growth with targeted nutrition support1R44HD110306-01A1 | NELSON, ELIZABETH RANDALL | MOTHER'S MILK IS BEST, INC., MA | $1,032,045 | ZRG1 |
| 2023 | A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)1R44AI174332-01 · under PA-21-259 | FANGER, GARYFURLAN FREGUIA, CHRISTIAN | RISE THERAPEUTICS, LLC, MD | $1,026,596 | ZRG1 |
| 2023 | Manganese-based Contrast Agent for Cardiovascular MRI2R44HL156713-02 | HOFFMAN, VERA | REVEAL PHARMA, MA | $1,026,595 | ZRG1 |
| 2023 | Hybrid ELISA: Simple and specific one-tier assay for Lyme disease2R44AI142903-03A1 | LEVIN, ANDREW E. | KEPHERA DIAGNOSTICS, LLC, MA | $1,025,000 | ZRG1 |
| 2023 | IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes2R44AI136201-04 | SHAH, SARJANSMITH, THOMAS J. | AURITEC PHARMACEUTICALS, INC., CA | $1,025,000 | ZRG1 |
| 2023 | Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma2R44CA254756-02A1 | OFFERMANN, MARGARET KENNY | ONCOSPHERIX, INC., GA | $1,024,999 | ZRG1 |
Showing the 200 most recent of 7,012 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.